Research Analysts Issue Forecasts for PRAX FY2030 Earnings

Key Points

• HC Wainwright slightly lowered its FY2030 EPS estimate for Praxis Precision Medicines to $129.08 from $129.38, while keeping a Buy rating and a $1,245 price target on the stock.
• Praxis reported first-quarter earnings of ($3.20) per share, beating the consensus estimate of ($3.58) and signaling a smaller-than-expected loss.
• The company’s pipeline gained momentum as the FDA accepted NDA filings for ulixacaltamide in essential tremor and relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies, creating potential regulatory catalysts in 2026-2027.

Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Free Report) - Equities research analysts at HC Wainwright lowered their FY2030 EPS estimates for shares of Praxis Precision Medicines in a report issued on Friday, May 8th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $129.08 for the year, down from their prior forecast of $129.38. HC Wainwright currently has a "Buy" rating and a $1,245.00 target price on the stock. The consensus estimate for Praxis Precision Medicines' current full-year earnings is ($15.16) per share.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its earnings results on Thursday, May 7th. The company reported ($3.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.58) by $0.38.

PRAX has been the subject of a number of other research reports. Deutsche Bank Aktiengesellschaft set a $420.00 price objective on Praxis Precision Medicines in a research report on Friday. Guggenheim restated a "buy" rating and issued a $800.00 target price (up from $760.00) on shares of Praxis Precision Medicines in a report on Tuesday, February 10th. Raymond James Financial began coverage on shares of Praxis Precision Medicines in a research note on Friday, April 10th. They set a "strong-buy" rating and a $815.00 price target on the stock. Truist Financial upgraded shares of Praxis Precision Medicines to a "strong-buy" rating in a report on Wednesday, March 25th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Praxis Precision Medicines in a research report on Thursday. Five investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Praxis Precision Medicines presently has a consensus rating of "Buy" and a consensus price target of $591.83.

Praxis Precision Medicines Price Performance

NASDAQ PRAX opened at $330.02 on Monday. Praxis Precision Medicines has a fifty-two week low of $35.21 and a fifty-two week high of $356.00. The business has a fifty day moving average of $317.78 and a 200-day moving average of $277.56. The stock has a market cap of $9.20 billion, a price-to-earnings ratio of -24.68 and a beta of 2.76.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of PRAX. NBC Securities Inc. purchased a new stake in Praxis Precision Medicines in the fourth quarter valued at approximately $38,000. Parallel Advisors LLC raised its stake in Praxis Precision Medicines by 3,000.0% during the first quarter. Parallel Advisors LLC now owns 124 shares of the company's stock worth $40,000 after purchasing an additional 120 shares during the period. Danske Bank A S acquired a new position in shares of Praxis Precision Medicines in the 4th quarter valued at $59,000. GAMMA Investing LLC boosted its holdings in shares of Praxis Precision Medicines by 58.7% in the 4th quarter. GAMMA Investing LLC now owns 238 shares of the company's stock valued at $70,000 after purchasing an additional 88 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Praxis Precision Medicines by 24.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company's stock valued at $77,000 after buying an additional 359 shares during the period. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Praxis Precision Medicines

Here are the key news stories impacting Praxis Precision Medicines this week:

• Positive Sentiment: The company reported first-quarter 2026 results with a smaller-than-expected loss, as EPS of ($3.20) beat estimates of ($3.58), which can help reassure investors ahead of future commercialization. Praxis earnings report
• Positive Sentiment: Praxis said the FDA accepted NDA filings for ulixacaltamide in essential tremor and relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies, giving the pipeline clearer regulatory timelines and potential catalysts in 2026-2027. Corporate update and Q1 2026 results
• Neutral Sentiment: BTIG reiterated a Buy rating and raised its price target sharply to $843, signaling strong long-term optimism even after the stock’s recent run-up. BTIG research update
• Negative Sentiment: Wedbush raised its target to $166 but kept an Underperform rating, highlighting meaningful downside risk versus the current share price and creating a conflicting message for investors. Wedbush rating update
• Neutral Sentiment: A Globe and Mail article noted analysts are bullish on Praxis alongside other healthcare names, adding to the broader positive attention on the stock. Analysts bullish on PRAX

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company's pipeline includes several lead candidates at various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.